Representative April McClain Delaney (Democratic-Maryland) recently sold shares of Labcorp Holdings Inc. (NYSE:LH). In a filing disclosed on September 09th, the Representative disclosed that they had sold between $1,001 and $15,000 in Labcorp stock on August 5th.
Representative April McClain Delaney also recently made the following trade(s):
- Sold $100,001 – $250,000 in shares of Wabtec (NYSE:WAB) on 8/25/2026.
- Sold $100,001 – $250,000 in shares of Viking (NYSE:VIK) on 8/25/2026.
- Sold $100,001 – $250,000 in shares of Trimble (NASDAQ:TRMB) on 8/25/2026.
- Sold $100,001 – $250,000 in shares of Transdigm Group (NYSE:TDG) on 8/25/2026.
- Sold $15,001 – $50,000 in shares of Tractor Supply (NASDAQ:TSCO) on 8/25/2026.
- Sold $15,001 – $50,000 in shares of Middleby (NASDAQ:MIDD) on 8/25/2026.
- Sold $15,001 – $50,000 in shares of Teledyne Technologies (NYSE:TDY) on 8/25/2026.
- Sold $100,001 – $250,000 in shares of STERIS (NYSE:STE) on 8/25/2026.
- Sold $100,001 – $250,000 in shares of Somnigroup International (NYSE:SGI) on 8/25/2026.
- Sold $100,001 – $250,000 in shares of Signet Jewelers (NYSE:SIG) on 8/25/2026.
Labcorp Stock Up 1.4%
Shares of NYSE LH traded up $4.40 during trading on Friday, hitting $311.36. 809,927 shares of the company traded hands, compared to its average volume of 635,612. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.53 and a current ratio of 1.80. The business’s fifty day moving average is $310.39 and its 200 day moving average is $281.94. The firm has a market capitalization of $25.25 billion, a price-to-earnings ratio of 25.75, a P/E/G ratio of 1.74 and a beta of 0.88. Labcorp Holdings Inc. has a fifty-two week low of $244.52 and a fifty-two week high of $341.80.
Labcorp Dividend Announcement
The business also recently disclosed a quarterly dividend, which was paid on Friday, September 11th. Stockholders of record on Friday, August 28th were issued a dividend of $0.72 per share. The ex-dividend date was Friday, August 28th. This represents a $2.88 annualized dividend and a dividend yield of 0.9%. Labcorp’s dividend payout ratio is currently 23.82%.
Trending Headlines about Labcorp
Here are the key news stories impacting Labcorp this week:
- Positive Sentiment: Labcorp reaffirmed its 2026 guidance of adjusted EPS of $18.10 to $18.55, broadly consistent with the analyst consensus of $18.32. Maintaining guidance supports confidence in near-term earnings visibility. Labcorp Holdings Reiterates 2026 Outlook, Issues Long-Term Guidance
- Positive Sentiment: The company issued a 2029 outlook calling for compound annual revenue growth of 5% to 8% and adjusted EPS growth of 8.5% to 11.5%. The targets imply sustained expansion beyond the current year and could support a higher long-term earnings outlook. Labcorp 2026 Investor Day Announcement
- Positive Sentiment: Labcorp plans to use artificial intelligence, specialty testing, scientific capabilities and global scale to drive growth. Management also emphasized strong cash-flow generation and disciplined capital deployment, which may improve shareholder returns if execution meets expectations. Labcorp Bets Big on AI and Specialty Testing
- Neutral Sentiment: The Investor Day transcript provided additional detail on Labcorp’s strategic priorities and long-term financial framework, but the benefits depend on successful implementation and investment in new technologies and testing capabilities. Labcorp Analyst and Investor Day Transcript
- Negative Sentiment: LH recently declined about 4.3% and underperformed peers, indicating that investors may have viewed the Investor Day information as insufficient to justify the stock’s elevated valuation or may have taken profits despite the favorable long-term targets. Labcorp Stock Heads Into the Open After a 4.3 Percent Slide
Insiders Place Their Bets
In other Labcorp news, CEO Adam Schechter sold 4,669 shares of the business’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $320.37, for a total transaction of $1,495,807.53. Following the sale, the chief executive officer owned 102,565 shares of the company’s stock, valued at $32,858,749.05. The trade was a 4.35% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Kathryn Kyle sold 92 shares of the firm’s stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $286.19, for a total value of $26,329.48. Following the completion of the transaction, the executive vice president owned 3,904 shares of the company’s stock, valued at approximately $1,117,285.76. This represents a 2.30% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 8,919 shares of company stock worth $2,826,593 in the last three months. Insiders own 0.84% of the company’s stock.
Analysts Set New Price Targets
A number of equities analysts have recently weighed in on LH shares. Wall Street Zen raised Labcorp from a “hold” rating to a “buy” rating in a research report on Sunday, July 12th. Robert W. Baird set a $352.00 price objective on shares of Labcorp in a report on Friday, July 31st. Weiss Ratings raised shares of Labcorp from a “buy (b-)” rating to a “buy (b)” rating in a research report on Friday, July 24th. Mizuho set a $355.00 price target on shares of Labcorp in a research report on Monday, August 10th. Finally, UBS Group lifted their price target on Labcorp from $361.00 to $380.00 and gave the company a “buy” rating in a research note on Friday. Nine investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $336.36.
Check Out Our Latest Stock Report on Labcorp
Institutional Investors Weigh In On Labcorp
A number of hedge funds have recently modified their holdings of the stock. Hilton Head Capital Partners LLC bought a new stake in Labcorp in the 4th quarter valued at about $27,000. JPL Wealth Management LLC bought a new stake in shares of Labcorp in the third quarter valued at approximately $28,000. DV Equities LLC purchased a new stake in shares of Labcorp during the 4th quarter valued at approximately $29,000. Allied Private Wealth LLC purchased a new stake in shares of Labcorp during the 2nd quarter valued at approximately $33,000. Finally, EFG International AG bought a new position in Labcorp in the 4th quarter worth approximately $33,000. Institutional investors own 95.94% of the company’s stock.
About Representative McClain Delaney
April McClain-Delaney (Democratic Party) is a member of the U.S. House, representing Maryland’s 6th Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.
McClain-Delaney (Democratic Party) is running for re-election to the U.S. House to represent Maryland’s 6th Congressional District. She declared candidacy for the 2026 election.
April McClain-Delaney grew up in Buhl, Idaho, where her father was a potato farmer. She obtained her bachelor’s degree in communications from Northwestern University in 1986 and her law degree from Georgetown Law Center in 1989. McClain-Delaney worked in communications law, first with the satellite firm Orion Network Systems and later as the Washington director for Common Sense Media, a nonprofit focused on technology and children. In 2022, McClain-Delaney joined the U.S. Department of Commerce under President Joe Biden (D) as deputy assistant secretary for communications and information. McClain-Delaney served on the board of the Georgetown University Law Center, the International Center for Research on Women, and the Northwestern University School of Communications.
Labcorp Company Profile
Labcorp (NYSE: LH), formerly Laboratory Corporation of America Holdings, is a global life sciences and laboratory services company headquartered in Burlington, North Carolina. The company provides diagnostic testing and related services to physicians, hospitals, health systems, employers, government agencies and consumers.
Its diagnostics business offers routine and specialty laboratory testing, including molecular, genetic, oncology, women’s health, infectious disease and pathology services.
Featured Stories
- Five stocks we like better than Labcorp
- Rocket Lab Tackles a Supply Chain Bottleneck as the Stock Hunts for a Bottom. Time to Buy?
- Optical Cable Corporation Is Starting to Get the Market’s Attention
- Oil Above $100 Is Creating a New Opportunity Beyond the Major Producers
- Is Nike’s Index Demotion a Warning or a Buying Opportunity?
Receive News & Ratings for Labcorp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Labcorp and related companies with MarketBeat.com's FREE daily email newsletter.
